However, this model was based on a process that was largely dependent on physical contact. The “social distancing” and strict COVID prevention policies meant that the model was unviable. Both pharmaceutical companies and PSP providers needed to rethink the entire PSP model and design and implement one that was better suited for the COVID and post pandemic era.
Pharmaceutical companies no longer control access to the PSP. Hence, cannot be sure of patient profiles included in the program. The program may include both approved and unapproved indications as discretion in patient selection lies with the doctor only.
Partnering with online pharmacies for running PSP means complete loss of company and product branding as well as inability to provide services other than drug supply as customization of PSP is difficult in this situation.
Difficult to track patients and follow up on outcomes
1. We help build a Patient Community of intrest to you (E.g.Rare disease and specialty)
2. We help the community improve its health outcomes by strengthening patient advocacy capabilities through training and empowering their representatives (NGO or patients Groups)
3. We build digital crowd funding platform for the patient community to reduce payments to platform provides outside community
4. We empower the community run comprehensive disease specific programs involving the important stakeholders like government and corporate sponsors
5. We strive to find partners like PONSIST that will help them improve outcomes for the community through greater engagement and collaboration among HCP
6. We enable companies build their brands through branded awereness PR and educational initiatives
7. We analyze Patients profile, experiences and current health status and challenges to the community
8. We provide valuable insights to prospective customers that can shape their marketing or doctor/patient engagement programs